Hims & Hers Health, Inc. (NYSE:HIMS) Receives $32.53 Consensus PT from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned a consensus rating of “Hold” from the seventeen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $31.8571.

HIMS has been the topic of several recent research reports. Barclays increased their price objective on Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 11th. Needham & Company LLC upgraded Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research report on Monday, March 9th. Truist Financial restated a “hold” rating and issued a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. BTIG Research cut Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Finally, Leerink Partners raised their price target on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 36,922 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $25.90, for a total value of $956,279.80. Following the transaction, the chief financial officer owned 281,867 shares in the company, valued at approximately $7,300,355.30. This trade represents a 11.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the transaction, the insider owned 8,752 shares in the company, valued at $216,086.88. The trade was a 38.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 204,857 shares of company stock worth $5,285,706 over the last three months. Company insiders own 13.71% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Pathway Capital Management LP bought a new position in Hims & Hers Health in the third quarter valued at about $6,766,000. Steadview Capital Management LLC grew its position in Hims & Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after acquiring an additional 311,845 shares during the last quarter. Farallon Capital Management LLC grew its position in Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the last quarter. BIT Capital GmbH grew its position in Hims & Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after acquiring an additional 938,728 shares during the last quarter. Finally, State of Michigan Retirement System grew its position in Hims & Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after acquiring an additional 678,600 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 2.4%

HIMS stock opened at $26.97 on Thursday. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The stock has a market capitalization of $6.15 billion, a price-to-earnings ratio of 52.88, a PEG ratio of 2.72 and a beta of 2.43. The business’s fifty day moving average price is $22.36 and its two-hundred day moving average price is $29.92. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.11 EPS. On average, equities analysts anticipate that Hims & Hers Health will post 0.56 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.